Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Half Year ended September 30, 2026 (Q2 FY27, H1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting and Un-audited Standalone Financial Results

Date of Board Meeting / Approval: October 17, 2026 (4:00 p.m. to 4:24 p.m.)

Audit Opinion: Clean (Unmodified review conclusion)

Auditor’s Comment: Nothing has come to our attention that causes us to believe that the accompanying Statement... contains any material misstatement.

Key Financial Highlights [Rs. in Lakhs]

Standalone Results:

Quarter Ended 30 September 2026:

  • Revenue from Operations: ₹17,690.16 (vs. ₹14,791.49 in Q2 FY26, +19.6% YoY)
  • Total Income: ₹17,779.40
  • Net Profit from Continuing Operations: ₹1,437.98
  • Net Profit for the period (including discontinued ops): ₹1,409.40
  • EPS (Basic) from Continuing Operations: ₹4.27
  • EPS (Basic) Total: ₹4.19

Half Year Ended 30 September 2026:

  • Revenue from Operations: ₹34,153.33 (vs. ₹29,675.12 in H1 FY26, +15.1% YoY)
  • Total Income: ₹34,323.71
  • Net Profit from Continuing Operations: ₹2,827.26
  • Net Profit for the period (including discontinued ops): ₹2,779.20
  • EPS (Basic) from Continuing Operations: ₹8.40
  • EPS (Basic) Total: ₹8.26

Balance Sheet as at 30 September 2026:

  • Paid-up equity share capital: ₹1,683.26 lakhs (Face Value ₹5 per share)
  • Other Equity: ₹54,032.85 lakhs (vs. ₹51,617.10 lakhs as at 31 March 2026)
  • Cash and cash equivalents: ₹1,347.32 lakhs (vs. ₹3,723.54 lakhs as at 31 March 2026)
  • Total Borrowings: ₹26,751.77 lakhs (Non-current: ₹7,038.06; Current: ₹19,713.71)
  • Total Assets: ₹98,114.81 lakhs

Segment-wise Performance:

The Company has identified only one reportable segment i.e. Pharmaceuticals.

Corporate Actions:

Not Specified

Other Significant Information:

Discontinued Operations:

The results include a loss from discontinued operations related to units approved for sale. For Q2 FY27, the loss after tax from discontinued operations was ₹(28.58) lakhs. Subsequent to the quarter, the Company completed the sale of its Plot No. D-2/CH/42 & D-2/CH/43 Dahej Industrial Area, GIDC, Bharuch, Gujarat.

Genrx Pharmaceuticals Acquisition:

In April 2025, the Company agreed to acquire Genrx Pharmaceuticals Private Limited for ₹1,085.00 lakhs. On 13 October 2026, the Company received an order from the NCLT approving the acquisition. Genrx will become a wholly owned subsidiary subject to completion of formalities.

Preferential Issue Fund Utilisation:

Funds raised through a preferential issue (₹20,497.00 lakhs) have been utilised primarily for loan repayment (₹15,000.00 lakhs) and capital expenditure (₹2,012.48 lakhs out of ₹3,500.00 allotted). An unutilised balance of ₹591.04 lakhs remains.

Assets Held for Sale:

The Board approved the sale of its unit at Plot No. N-178, MIDC, Tarapur on 23 June 2026. It is classified as Property Held for Sale as at 30 September 2026, with an expected transaction conclusion by 31 October 2026.